 Enzyme Inhibitors
"Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
| Descriptor ID |
D004791
|
| MeSH Number(s) |
D27.505.519.389
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Enzyme Inhibitors".
This graph shows the total number of publications written about "Enzyme Inhibitors" by people in this website by year, and whether "Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 1 | 1 | | 1982 | 0 | 1 | 1 | | 1987 | 2 | 0 | 2 | | 1990 | 0 | 1 | 1 | | 1995 | 2 | 8 | 10 | | 1996 | 3 | 19 | 22 | | 1997 | 5 | 17 | 22 | | 1998 | 7 | 14 | 21 | | 1999 | 2 | 21 | 23 | | 2000 | 7 | 21 | 28 | | 2001 | 4 | 25 | 29 | | 2002 | 8 | 39 | 47 | | 2003 | 9 | 28 | 37 | | 2004 | 6 | 20 | 26 | | 2005 | 9 | 16 | 25 | | 2006 | 6 | 20 | 26 | | 2007 | 8 | 7 | 15 | | 2008 | 3 | 17 | 20 | | 2009 | 8 | 15 | 23 | | 2010 | 10 | 8 | 18 | | 2011 | 6 | 12 | 18 | | 2012 | 3 | 12 | 15 | | 2013 | 5 | 10 | 15 | | 2014 | 7 | 6 | 13 | | 2015 | 6 | 5 | 11 | | 2016 | 5 | 5 | 10 | | 2017 | 7 | 1 | 8 | | 2018 | 9 | 5 | 14 | | 2019 | 9 | 4 | 13 | | 2020 | 5 | 4 | 9 | | 2021 | 5 | 2 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Enzyme Inhibitors" by people in Profiles.
-
Azizi SA, Lan T, Delalande C, Kathayat RS, Banales Mejia F, Qin A, Brookes N, Sandoval PJ, Dickinson BC. Development of an Acrylamide-Based Inhibitor of Protein S-Acylation. ACS Chem Biol. 2021 08 20; 16(8):1546-1556.
-
Richter WF, Shah RN, Ruthenburg AJ. Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia. Elife. 2021 07 15; 10.
-
Mascarenhas J, Komrokji RS, Palandri F, Martino B, Niederwieser D, Reiter A, Scott BL, Baer MR, Hoffman R, Odenike O, Vannucchi AM, Bussolari J, Zhu E, Rose E, Sherman L, Dougherty S, Sun L, Huang F, Wan Y, Feller FM, Rizo A, Kiladjian JJ. Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis. J Clin Oncol. 2021 09 10; 39(26):2881-2892.
-
Khan M, Roddy JT, Hernandez JR, Bursch K, Bal N, Carlson KS, Bergl PA. Revisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH-inhibitor therapy for AML. Br J Haematol. 2021 09; 194(6):1083-1085.
-
Kim Y, Wower J, Maltseva N, Chang C, Jedrzejczak R, Wilamowski M, Kang S, Nicolaescu V, Randall G, Michalska K, Joachimiak A. Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2. Commun Biol. 2021 02 09; 4(1):193.
-
Lheureux S, Cristea MC, Bruce JP, Garg S, Cabanero M, Mantia-Smaldone G, Olawaiye AB, Ellard SL, Weberpals JI, Wahner Hendrickson AE, Fleming GF, Welch S, Dhani NC, Stockley T, Rath P, Karakasis K, Jones GN, Jenkins S, Rodriguez-Canales J, Tracy M, Tan Q, Bowering V, Udagani S, Wang L, Kunos CA, Chen E, Pugh TJ, Oza AM. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 01 23; 397(10271):281-292.
-
Pan M, Zheng Q, Yu Y, Ai H, Xie Y, Zeng X, Wang C, Liu L, Zhao M. Seesaw conformations of Npl4 in the human p97 complex and the inhibitory mechanism of a disulfiram derivative. Nat Commun. 2021 01 05; 12(1):121.
-
Kim J, Lee HM, Cai F, Ko B, Yang C, Lieu EL, Muhammad N, Rhyne S, Li K, Haloul M, Gu W, Faubert B, Kaushik AK, Cai L, Kasiri S, Marriam U, Nham K, Girard L, Wang H, Sun X, Kim J, Minna JD, Unsal-Kacmaz K, DeBerardinis RJ. The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer. Nat Metab. 2020 12; 2(12):1401-1412.
-
You Q, Cheng AY, Gu X, Harada BT, Yu M, Wu T, Ren B, Ouyang Z, He C. Direct DNA crosslinking with CAP-C uncovers transcription-dependent chromatin organization at high resolution. Nat Biotechnol. 2021 02; 39(2):225-235.
-
Cheong EJY, Nair PC, Neo RWY, Tu HT, Lin F, Chiong E, Esuvaranathan K, Fan H, Szmulewitz RZ, Peer CJ, Figg WD, Chai CLL, Miners JO, Chan ECY. Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen. J Pharmacol Exp Ther. 2020 09; 374(3):438-451.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|